Solid Biosciences Inc.’s SLDB share price has surged by 5.57%, which has investors questioning if this is right time to sell.

A diagnosis that could shape your future might be resting on outdated rules. For decades, the key number used to flag a ...

Tenaya Therapeutics, Inc.’s TNYA share price has dipped by 6.21%, which has investors questioning if this is right time to ...

BridgeBio's new heart drug — a rival to Pfizer's blockbuster Vyndaqel — smashed sales expectations in its first full quarter ...

Our coverage of ACC 2025 in Chicago dominated our most-read stories, but other news on novel therapies made the list, too.

Results of the VANISH-2 trial, building on prior research, further upheld superiority of catheter ablation over ...

Four new original research articles published in Annals of Family Medicine examine how digital tools are being tested to ...

Despite formidable competition in the growing transthyretin amyloid cardiomyopathy (ATTR-CM) market, a strong early launch ...

Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic ...

UK MHRA grants marketing approval for BridgeBio Pharma’s Beyonttra to treat ATTR-CM: Palo Alto, California Wednesday, April 30, 2025, 16:00 Hrs [IST] BridgeBio Pharma, Inc., a n ...

A mom whose daughter died in a crash listened to her heart beat again after it was donated to an eight-year-old girl. Lisa ...

Renowned singer Tank from Taiwan recently underwent a simultaneous heart and liver transplant to treat a serious genetic ...